Comparing wearable glucose devices: CGM and intermittently scanned systems
Wearable glucose devices refer to skin-worn sensors that monitor blood sugar signals continuously or when scanned. These systems include real-time continuous glucose monitors and intermittently scanned sensors that store readings for later review. This piece explains device types, how sensors measure glucose, regulatory and clinical evidence, accuracy and typical use cases, prescription and reimbursement factors, data integration, maintenance needs, and practical trade-offs to weigh when comparing options.
Types of wearable glucose devices
Two device families dominate current use. Real-time continuous glucose monitors stream readings to a receiver or phone every few minutes and can produce on-device alerts for low or high glucose. Intermittently scanned systems store glucose readings in the sensor; a phone or reader must be brought close to the sensor to retrieve data. Both are worn on the body, usually on the upper arm or abdomen, and use a thin filament beneath the skin to sample interstitial fluid.
How sensors measure glucose and present data
Wearable sensors use a chemical enzyme on a tiny probe that reacts with glucose in interstitial fluid. That reaction creates an electrical signal, which the device converts into a glucose number and trend information. Readouts typically show current glucose, a short trend arrow, and a historic trace across hours or days. Real-time models push alerts to phones and share data continuously with connected devices. Intermittently scanned models show the same types of readings but only when scanned, so alerts and automatic remote sharing are limited or absent.
Regulatory approvals and clinical evidence
Most commercially available sensors have approvals from regional regulators such as the U.S. Food and Drug Administration or a European conformity mark. Regulators assess safety, manufacturing quality, and measured accuracy before clearance. Clinical evidence comes from randomized trials, observational studies, and registry reports. These studies commonly evaluate time spent in target glucose ranges, frequency of low glucose episodes, and user satisfaction. Evidence often shows improvements in glucose time-in-range for people using continuous monitoring, but results vary by population, device model, and how the device is used alongside insulin or other treatments.
Accuracy, common failure modes, and typical use cases
Device accuracy is commonly expressed as mean absolute relative difference (MARD), a summary of how sensor readings compare with laboratory glucose. Many modern sensors report MARD in the single digits to low teens, roughly 8–13 percent for several current models. Accuracy depends on factors like sensor age, placement, hydration, and rapid glucose changes. Common failure modes include sensor adhesion problems, skin irritation, signal dropouts, pressure-induced errors when the site is compressed, and occasional calibration drift with older models. Typical use cases range from people using insulin multiple times per day to those who want trends and fewer fingersticks. Intermittently scanned sensors suit people who check frequently in person; real-time systems are often preferred where alarms and remote sharing matter.
| Feature | Real-time CGM | Intermittently scanned CGM |
|---|---|---|
| Data flow | Continuous streaming to phone/receiver | Stored in sensor, read when scanned |
| Alerts | Proactive low/high alerts available | Limited or no automatic alerts |
| Wear duration | 7–14 days typical (model dependent) | 10–14 days common (model dependent) |
| Calibration | Many models factory-calibrated | Often factory-calibrated, few require fingerstick |
| Accuracy range | Approximately 8–13% MARD for many models | Approximately 9–15% MARD for many models |
| Typical users | People needing alarms, remote sharing, tight control | People who scan frequently and want trend review |
Eligibility, prescription, and reimbursement considerations
Access typically requires a prescription in many healthcare systems. Eligibility criteria differ by payer: some cover devices for people on intensive insulin therapy, recurrent low glucose, or specific clinical conditions. Reimbursement rules change by country and insurer and may set documentation requirements such as glucose logs or clinical notes. Durable supplies—sensors, transmitters, and adhesives—often need regular refills. People should expect discussions with clinicians or diabetes educators about documented need and about which supplies are included under a plan.
Integration with apps and interoperability
Most devices connect to manufacturer apps for on-device display and long-term reports. Many systems permit data sharing with family members, caregivers, or clinical portals. Third-party apps and smart insulin pumps can integrate with some sensors, enabling automated insulin adjustments in select systems. Interoperability varies: some setups use open data standards and third-party tools, while others rely on manufacturer ecosystems. When comparing devices, check whether the system shares data with the apps or devices already in use.
Maintenance, calibration, and supply needs
Sensors are single-use consumables with set wear times and must be replaced on schedule. Transmitters may last months and need periodic replacement. Older models required routine fingerstick calibration; many newer sensors arrive factory-calibrated and do not require daily fingersticks, although confirmatory fingerstick checks are sometimes recommended during rapid glucose changes. Adhesive patches and sensor replacements create a recurring cost and logistic need, and some people find adhesives require supplementary tape or patches for secure wear during sports or heat.
Trade-offs: convenience, accuracy, and cost
Choosing a wearable glucose device is about balancing goals. Real-time systems offer alarms and continuous remote sharing at the cost of higher ongoing supply needs for some users. Intermittently scanned systems reduce alerts and continuous data but can be cheaper and simpler for people who scan regularly. Accuracy gains have narrowed across device types, but performance can shift depending on activity, hydration, and sensor age. Study results come from specific populations and device models; improvements seen in trials may not appear the same way for every person, especially outside controlled settings. Consider the general accuracy range, likely supply cadence, and how much value is placed on alarms, remote data sharing, and automated insulin features.
Putting practical checkpoints in clinical discussions
Clinicians and people comparing devices should confirm regulatory clearance for the intended use, review peer-reviewed evidence for outcomes relevant to the patient, and check payer coverage rules. Discuss likely wear sites, daily routines that affect adhesion, the need for alarms or remote monitoring, and whether pump integration is a future need. A short trial period with close follow-up can reveal comfort, skin reaction, and real-world data fidelity before committing to a long-term supply plan.
How much does a continuous glucose monitor cost
What is CGM accuracy compared to fingerstick
Which wearable glucose sensor integrates with apps
Final observations on device comparison
Wearable glucose devices now offer choices tuned to different priorities: uninterrupted alerts and automated sharing for people who need tight, responsive control, or simpler scan-based systems for those who prefer fewer alarms and straightforward trend checks. Accuracy has improved across the market, but practical factors—adhesion, data sharing, supply cadence, and reimbursement—often guide the decision as much as raw performance figures. Use clinical conversations and payer information to narrow options, and treat short trials and real-world experience as part of the evaluation.
This article provides general information only and is not medical advice, diagnosis, or treatment. Health decisions should be made with qualified medical professionals who understand individual medical history and circumstances.
